Patent intelligence · US
US 12409225
Ras inhibitors
Ras inhibitors
Patent details — US 12409225
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 9, 2025
- Expiration
- Sep 4, 2045
- Applicant
- Revolution Medicines, Inc.
- Claims
- 23
- CPC classes
- A61K, A61K45/06, A61P, A61P35/00
Quick answer
US 12409225 (Ras inhibitors) is held by Revolution Medicines, Inc.. Status: granted. Granted Sep 9, 2025. Expires Sep 4, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Revolution Medicines, Inc.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K45/06, A61P, A61P35/00
More from Revolution Medicines, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403196
Ras inhibitors
granted -
US 12384750
Ras inhibitors
granted -
US 12365688
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
granted -
US 12280113
Ras inhibitors
granted -
US 12258366
Bicyclic heteroaryl compounds and uses thereof
granted -
US 12252497
Ras inhibitors
granted -
US 12202845
Ras inhibitors
granted
Frequently asked questions
What is US patent 12409225?
US 12409225 (Ras inhibitors) is held by Revolution Medicines, Inc.. Status: granted. Granted Sep 9, 2025. Expires Sep 4, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12409225?
Revolution Medicines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 12409225 expire?
Our index shows an expiration date of Sep 4, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.